Polymeric nanoparticles for sustained down-regulation of annexin A2 lead to reduction in proliferation and migration of prostate cancer cells

Journal of Biomedical Nanotechnology

Volumn 3, Issue 2, 2007, Pages 148-159

  Braden, A ^a   Kashyap, A ^a   Vasir, J ^b   Labhasetwar, V ^b   Vishwanatha, J K ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Nanoparticle; PLGA; Prostate cancer; siRNA

Indexed keywords

LIPOCORTIN 2; NANOPARTICLE; PLASMID DNA; POLYGLACTIN; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MIGRATION INHIBITION; PROSTATE CANCER;

EID: 45849100910     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2007.010     Document Type: Article

References (29)

1. D. M. Waisman, Annexin A2 tetramer: Structure and function. Mol. Cell. Biochem. 149-150, 301 (1995).
2. C. Balch and J. R. Dedman, Annexins II and V inhibit cell migration. Exp. Cell Res. 237, 259 (1997).
3. S. Blanchard, J. L. Barwise, V. Gerke, A. Goodall, P. F. Vaughan, and J. H. Walker, Annexins in the human neuroblastoma SH-SY5Y. Demonstration of relocation of annexins II and V to membranes in response to elevation of intracellular calcium by membrane depolarisation and by the calcium ionophore A23187. J. Neurochem. 67, 805 (1996).
4. F. M. Brichory, D. E. Misek, A. M. Yim, M. C. Krause, T. J. Giordano, D. G. Beer, and S. M. Hanash, An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc. Natl. Acad. Sci. USA 98, 9824 (2001).
5. S. Choi, M. Kobayashi, J. Wang, H. Habelhah, F. Okada, J. Hamada, T. Moriuchi, Y. Totsuka, and M. Hosokawa, Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with adriamycin. Clin. Exp. Metastasis 18, 45 (2000).
6. K. Emoto, Y. Yamada, H. Sawada, H. Fujimoto, M. Ueno, T. Takayama, K. Kamada, A. Naito, S. Hirao, and Y. Nakajima, Annexin II overexpression correlates with stromal tenascin-C over-expression: a prognostic marker in colorectal carcinoma. Cancer 92, 1419 (2001).
7. D. Kaczan-Bourgois, J. P. Satles, and H. Chap, Expression of annexin II and associated p11 protein by differentiated choriocarcinoma jar cells. Am. J. Obstet. Gynecol. 181, 1273 (1999).
8. J. S. Menell, G. M. Cesarman, A. T. Jacovina, M. A. McLaughlin, E. A. Lev, and K. A. Hajjar, Annexin II and bleeding in acute promyelocytic leukemia. N. Engl. J. Med. 340, 904 (1999).
9. J. Mohiti, J. H. Walker, and A. M. Caswell, Studies on annexins in primary cultures of human osteoblasts and in the human osteosarcoma cell line MG-63. Biochem. Soc. Trans. 23, 36S (1995).
10. J. K. Vishwanatha, Y. Chiang, K. D. Kumble, M, A. Hollingsworth, and P. M. Pour, Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers. Carcinogenesis 14, 2575 (1993).
11. M. Aitkenhead, S. J. Wang, M. N. Nakatsu, J. Mestas, C. Heard, and C. C. Hughes, Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: Induction of ESM-1, (beta)ig-h3, and NrCAM. Microvasc. Res. 63, 159 (2002).
12. G. P. Tuszynski, M. R. Sharma, V. L. Rothman, and M. C. Sharma, Angiostatin binds to tyrosine kinase substrate annexin II through the lysine-binding domain in endothelial cells. Microvasc. Res. 64, 448 (2002).
13. G. M. Cesarman, C. A. Guevara, and K. A. Hajjar, An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA) II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J. Biological Chem. 269, 21198 (1994).
14. J. Mai, D. M. Waisman, and B. F. Sloane, Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochim. Biophys. Acta 1477, 215 (2000).
15. R. J. Tressfer, T. V. Updyke, T. Yeatman, and G. L. Nicolson, Extracellular annexin II is associated with divalent cation- dependent tumor cell-endothelial cell adhesion of metastatic RAW117 large-cell lymphoma cells. J. Cellular Biochem. 53, 265 (1993).
16. D. A. Eberhard, L. R. Karns, S. R. VandenBerg, and C. E. Creutz, Control of the nuclear-cytoplasmic partitioning of annexin II by a nuclear export signal and by p11 binding. J. Cell Sci. 114, 3155 (2001).
17. J. Liu, C. A. Rothermund, J. Ayala-Sanmartin, and J. K. Vishwanatha, Nuclear annexin II negatively regulates growth of LNCaP cells and substitution of ser 11 and 25 to glu prevents nucleo-cytoplasmic shuttling of annexin II. BMC Biochem. 4, 10 (2003).
18. J. K. Vishwanatha and S. Kumble, Involvement of annexin II in DNA replication: evidence from cell-free extracts of xenopus eggs. J. Cell Sci. 105, 533 (1993).
19. Y. Chiang, A. Rizzino, Z. A. Sibenaller, M. S. Wold, and J. K. Vishwanatha, Specific down-regulation of annexin II expression in human cells interferes with cell proliferation. Mol. Cell Biochem. 199, 139 (1999).
20. K. D. Kumble, P. L. Iversen, and J. K. Vishwanatha, The role of primer recognition proteins in DNA replication: Inhibition of cellular proliferation by antisense oligodeoxyribonucleotides. J. Cell Sci. 101, 35 (1992).
21. Q. Ling, A. T. Jacovina, A. Deora, M. Febbraio, R. Simantov, R. L. Silverstein, B. Hempstead, W. H. Mark, and K. A. Hajar, Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J. Clin. Invest 113, 38 (2004).
22. J. W. Liu, J. J. Shen, A. Tanzillo-Swarts, B. Bhatia, C. M. Maldonado, M. D. Person, S. S. Lau, and D. G. Tang, Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 22, 1475 (2003).
23. A. G. Banerjee, J. Liu, Y. Yuan, V. K. Gopalakrishnan, S. L. Johansson, A. K. Dinda, N. P. Gupta, L. Trevino, and J. K. Vishwanatha, Expression of biomarkers modulating prostate cancer angiogenesis: Differential expression of annexin II in prostate carcinomas from India and USA. Mol. Cancer 2, 34 (2003).
24. L. Tatenhorst, U. Reschert, V. Gerke, and W. Paulus, Knockdown of annexin 2 decreawses migration of human glioma cells in vitro. Neuropath. App. Neurobio. 32, 271 (2006).
25. M. Srivastava, L. Bubendorf, V. Srikantan, L. Fossom, L. Nolan, M. Glasman, X. Leighton, W. Fehrle, S. Pittaluga, and M. Raffeld, ANX7, a candidate tumor suppressor gene for prostate cancer. Proc. Natl. Acad. Sci. USA 98, 4575 (2001).
26. J. Panyam and V. Labhasetwar, Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55, 329 (2003).
27. J. Panyam, S. K. Sahoo, S. Prabha, T. Bargar, and V. Labhasetwar, Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles. Int. J. Pharm. 262, 1 (2003).
28. J. Panyam, W. Z. Zhou, S. Prabha, S. K. Sahoo, and V. Labhasetwar, Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 16, 1217 (2002).
29. K. Win and S. Feng, Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs, Biomaterials 26, 2713 (2005).